Phenomix Sciences uses precision medicine platform to predict obesity treatment outcomes
Click Here to Manage Email Alerts
Phenomix Sciences has launched their Phenomix Sciences Obesity Platform, a set of data and tools that personalize obesity treatments.
“The Platform was developed with a goal to combat obesity with data-driven medicine,” Mark Bagnall, CEO of Phenomix, told Healio. “Obesity isn’t one disease, but many, and at least four can be determined by phenotyping. In fact, the four phenotype categories account for 90% of obese patients. Phenomix is the first to bring a solution to market based on the science of phenotyping.”
The Phenomix Sciences Obesity Platform uses data from biological samples, behavioral assessments, clinical trial results and other variables to match a patient to a particular phenotype. The company has collected over 20 billion data points and launched a biobanking initiative, so that data can be analyzed using AI and machine learning to predict patient responses to treatment, according to a company press release.
“Phenomix is developing the first ever therapy selection test using data from this platform to predict patient responses to GLP-1 treatments,” Bagnall said. “While the success with these treatments has been proven, they aren’t the right fit for every patient. This test will give the entire obesity community data driven insight, which will in turn improve patient outcomes and lower overall health care costs.”
Read more about
Click Here to Manage Email Alerts